ReNeuron to participate in stem cell conference

RNS Number : 7928G
ReNeuron Group plc
18 May 2011
 



 

 

PRESS RELEASE

 

ReNeuron to participate at leading international stem cell conference

 

 

Guildford, UK, 18 May 2011: ReNeuron Group plc (LSE: RENE.L) announces that it is participating in the 17th International Society for Cellular Therapy Annual Meeting in Rotterdam, Netherlands on 18-21 May.

 

Dr John Sinden, Chief Scientific Officer of ReNeuron, will participate as the industry representative in a Global Regulatory Perspectives Workshop session focusing on the regulatory and operational issues associated with clinical trials of cell therapy products in Europe, the US and Asia.  Senior representatives from regulatory agencies in these territories make up the rest of the participants in this session at the conference.

 

Further information regarding the conference may be found at www.celltherapysociety.org.

 

Enquiries:

 

Michael Hunt, Chief Executive Officer - ReNeuron            +44 (0) 1483 302560

Dr John Sinden, Chief Scientific Officer - ReNeuron

                                   

Lisa Baderoon, Mark Court, Isabel Podda                        +44 (0) 20 7466 5000

Buchanan Communications                                      

 

Antony Legge, Oliver Rigby                                                  +44 (0) 20 7776 6550

Daniel Stewart & Company plc                              

 

James Gallagher, Tim Graham                                           +44 (0) 20 3206 7000

Matrix Corporate Capital LLP                                

 

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

 

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in early clinical development.  ReNeuron's ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

 

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research.  The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

 

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAVDLFFFEFZBBQ
UK 100

Latest directors dealings